Meta AnalysisID 1410
应用培门冬酶治疗儿童和青少年急性淋巴细胞白血病：一项系统评价
CRD42017072495
Is PEG-asparaginase more effective for the treatment of acute lymphoblastic leukaemia than other medications of the same class currently in use?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1410
- Evidence Id
- 9968
- Core Evidence Id
- 9968
- Source Meta Analysis Id
- 1365
- Herb2 Meta Analysis Id
- HBMA001365
- Crd Id
- CRD42017072495
- Title
- Pharmacological treatment of acute lymphoblastic leukemia in children and adolescents with a peg-asparaginase: a systematic review
- Review Question
- Is PEG-asparaginase more effective for the treatment of acute lymphoblastic leukaemia than other medications of the same class currently in use?
- Study Type Included
- We included randomized controlled trials.
- Condition Being Studied
- Leukemia is the childhood and juvenile cancer with a higher incidence in children and adolescents, and Acute Lymphoblastic Leukemia (ALL) is the most common subtype in this population, which presents a high survival rate in this group of individuals. Asparaginase is an enzyme extracted from the bacterium Echerichia coli effective in the treatment of ALL, but due to its immunogenic effects, many patients suspend their use during chemotherapy.
- Participant
- Children and adolescents (0 – 19 years).
- Animal
- Human Disease Modelled
- Intervention
- Asparaginase has several formulations, among them, the PEG-asparaginase, which has been formulated for the purpose of decreasing the immunogenic effects of the enzyme in the patient's body and thus avoiding treatment interruption.
- Comparator Control
- Other formulations of asparaginase, including a native Asparaginase derived from Escherichia coli.
- Main Outcome
- Efficacy in the treatment of ALL in comparison to the other formulations. Level of production of antiasparaginase antibodies. Event free- survival. Overall survival.
- Outcome Measure
- Additional Outcome
- Plasma levels of asparagina.
- Study Method
- Systematic review
- Keyword
- Adolescents; Asparaginase; Child; Humans; Pegaspargase; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Contact
- Camile Valle Medawar [email protected]
- Organisational Affiliation
- Pharmacy School - Federal Fluminense University. http://www.farmacia.uff.br
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Portuguese-Brazil
- Country
- Brazil
- Review Stage
- Review Ongoing
- First Submission Date
- 2017-12-07
- Registration Date
- 2017-07-19
- Anticipated Start Date
- 2017-08-01
- Anticipated Completion Date
- 2018-08-01
- Title Cn
- 应用培门冬酶治疗儿童和青少年急性淋巴细胞白血病：一项系统评价
- Title En
- Pharmacological treatment of acute lymphoblastic leukemia in children and adolescents with a peg-asparaginase: a systematic review
- Bilingual Status
- complete